Seth Klarman acquired 7.42 Million Theravance Biopharma shares worth $67.6 Million. That's 1.30% of their equity portfolio (17th largest holding). The investor owns 14.20% of the outstanding Theravance Biopharma stock. The first Theravance Biopharma trade was made in Q2 2014. Since then Seth Klarman bought shares eight more times and sold shares on six occasions. The investor's estimated purchase price is $174 Million, resulting in a loss of 61%.